Lexeo Therapeutics Acquires Mantle to Boost FA Pipeline and Extends Cash Runway to 2028

Key Facts

1Lexeo Therapeutics signed a definitive agreement to acquire Mantle Therapeutics to strengthen its Friedreich ataxia (FA) treatment portfolio.

2The company announced three new research collaborations aimed at optimizing cerebellar targeting for gene therapies.

3The company expects its current cash runway to support operations into 2028.

In a move reflecting the accelerating pace of biotech mergers to develop rare disease treatments, Lexeo Therapeutics announced a definitive agreement to acquire Mantle Therapeutics. This acquisition is designed to strengthen the company’s Friedreich ataxia (FA) portfolio by adding new therapeutic modalities to increase frataxin levels. Additionally, the company unveiled three new strategic research collaborations focused on optimizing cerebellar targeting, further cementing its leadership in the gene therapy space.

From a financial perspective, management confirmed that its current cash runway is sufficient to fund operations and research activities into 2028, providing a significant buffer before clinical trial data readouts. Per market data, LXEO shares closed at $4.08 on September 21, 2026, trading between a low of $4.04 and a high of $4.34 during that session, as investors weigh the impact of the company's strategic expansion.

Traders should monitor progress on the SUNRISE-FA 2 pivotal study, which remains the company’s top priority with topline data expected in the second half of 2027. Regarding the economic calendar, the market continues to digest the Fed Interest Rate Decision from September 16, 2026, which raised rates to 4%, a factor that may influence future financing costs for growth-stage biotech firms.